Publication: Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus
Issued Date
2018-08-10
Resource Type
ISSN
16643224
Other identifier(s)
2-s2.0-85054932485
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Immunology. Vol.9, No.AUG (2018)
Suggested Citation
Kuldeep Dhama, Kumaragurubaran Karthik, Rekha Khandia, Sandip Chakraborty, Ashok Munjal, Shyma K. Latheef, Deepak Kumar, Muthannan Andavar Ramakrishnan, Yashpal Singh Malik, Rajendra Singh, Satya Veer Singh Malik, Raj Kumar Singh, Wanpen Chaicumpa Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus. Frontiers in Immunology. Vol.9, No.AUG (2018). doi:10.3389/fimmu.2018.01803 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45989
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus
Abstract
© 2018 Dhama, Karthik, Khandia, Chakraborty, Munjal, Latheef, Kumar, Ramakrishnan, Malik, Singh, Malik, Singh and Chaicumpa. Ebola virus (EBOV), a member of the family Filoviridae, is responsible for causing Ebola virus disease (EVD) (formerly named Ebola hemorrhagic fever). This is a severe, often fatal illness with mortality rates varying from 50 to 90% in humans. Although the virus and associated disease has been recognized since 1976, it was only when the recent outbreak of EBOV in 2014-2016 highlighted the danger and global impact of this virus, necessitating the need for coming up with the effective vaccines and drugs to counter its pandemic threat. Albeit no commercial vaccine is available so far against EBOV, a few vaccine candidates are under evaluation and clinical trials to assess their prophylactic efficacy. These include recombinant viral vector (recombinant vesicular stomatitis virus vector, chimpanzee adenovirus type 3-vector, and modified vaccinia Ankara virus), Ebola virus-like particles, virus-like replicon particles, DNA, and plant-based vaccines. Due to improvement in the field of genomics and proteomics, epitope-targeted vaccines have gained top priority. Correspondingly, several therapies have also been developed, including immunoglobulins against specific viral structures small cell-penetrating antibody fragments that target intracellular EBOV proteins. Small interfering RNAs and oligomer-mediated inhibition have also been verified for EVD treatment. Other treatment options include viral entry inhibitors, transfusion of convalescent blood/serum, neutralizing antibodies, and gene expression inhibitors. Repurposed drugs, which have proven safety profiles, can be adapted after high-throughput screening for efficacy and potency for EVD treatment. Herbal and other natural products are also being explored for EVD treatment. Further studies to better understand the pathogenesis and antigenic structures of the virus can help in developing an effective vaccine and identifying appropriate antiviral targets. This review presents the recent advances in designing and developing vaccines, drugs, and therapies to counter the EBOV threat.